J&J to Cut 6-7% of Workforce in Restructuring - Companies * US * News * Story

Runway Angels
The superbowl of fashion shows, models walk down the runway at the 2009 Victoria's Secret Show.
Smartphone Guide
Here's a need-to-know guide to nine devices, based on features, price, network and platform.
Wines for the Holidays
Not quite sure what wine to pair with Turkey or Creme Brulee? Our experts do.

FEATURED QUIZZES

A Healthier & Wealthier You
Take the following quiz and find out how much you know about the impact of obesity on the health of the U.S. economy.
The Billionaire BFF's
Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?
The Many Myths of Coca-Cola
Can you tell which statements are true, and which ones are just rumors?

SPECIAL REPORTS

Winterizing Your Portfolio
If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.
Investor's Guide to Real Estate
Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.
Alternative Investing
Stocks and bonds? Sure. But it's a big world out there for investors.

CNBC ON DIGG

J&J to Cut 6-7% of Workforce in Restructuring

Published: Monday, 9 Nov 2009 | 3:48 PM ET

Text Size

By: Reuters

Johnson & Johnson said on Tuesday it plans to cut 6 percent to 7 percent of its workforce in a battle to prop up profits in the face of generic competition to its prescription drugs.

The company said the cuts will affect 7,000 to 8,000 jobs, and generate annualized cost savings of $1.4 billion to $1.7 billion in 2011, with $800 million to $900 million expected to be achieved in 2010.

J&J [JNJ Loading... () ], which employs about 117,000 people worldwide, said it will take a charge of $1.1 billion to $1.3 billion against its fourth-quarter earnings, but did not change its 2009 earnings forecast excluding one-time items of $4.54 to $4.59 per share.

The cuts will mainly be achieved by reducing layers of management and simplifying business structures and processes, the company said in a statement.

J&J is more diversified than some of its rivals. William Weldon, the company's chief executive officer, said the cuts are designed to ensure its broad-based operating model remains appropriately structured for long-term growth.

RELATED LINKS

J&J joins the growing list of major pharmaceutical companies to slash jobs as big-selling drugs lose patent protection. J&J's prescription drug sales fell more than 14 percent to $5.25 billion in the third quarter, hurt by generic competition to its epilepsy drug Topamax and schizophrenia drug Risperdal.

The company said the job cuts will form only one component of the savings and it will also seek savings at the operating level. The company has a global workforce of 117,000.

Drug companies are struggling to refill their pipelines with new drugs to offset sales lost to generic competition, and although they are acquiring products from biotechnology companies, the new products are not enough.

Pfizer [PFE Loading... () ], Merck [MRK Loading... () ] and Bristol-Myers Squibb [BMY Loading... () ] have all announced sweeping job cuts, as have British drugmakers GlaxoSmithKline [GSK Loading... () ] and AstraZeneca [AZN Loading... () ].